Shares of Natera, Inc. (NASDAQ:NTRA - Get Free Report) have been given an average rating of "Buy" by the sixteen analysts that are currently covering the firm, MarketBeat Ratings reports. Fifteen analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $192.5333.
A number of equities analysts have recently weighed in on NTRA shares. Evercore ISI upgraded Natera to a "strong-buy" rating and set a $170.00 target price on the stock in a research note on Monday, July 28th. UBS Group increased their target price on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. Royal Bank Of Canada raised their price objective on Natera from $251.00 to $255.00 and gave the stock an "outperform" rating in a research note on Friday. Barclays restated an "overweight" rating and set a $210.00 price objective (up previously from $190.00) on shares of Natera in a research note on Friday. Finally, Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th.
View Our Latest Analysis on NTRA
Natera Trading Up 7.7%
Shares of NASDAQ NTRA opened at $151.95 on Monday. The firm has a market cap of $20.75 billion, a P/E ratio of -79.55 and a beta of 1.76. Natera has a 1-year low of $104.00 and a 1-year high of $183.00. The business's 50 day moving average is $155.60 and its 200-day moving average is $154.85.
Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The firm had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative return on equity of 22.93% and a negative net margin of 12.89%. Natera's revenue for the quarter was up 32.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.30) EPS. Analysts forecast that Natera will post -1.49 EPS for the current year.
Insider Transactions at Natera
In other Natera news, insider Solomon Moshkevich sold 3,000 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $132.89, for a total value of $398,670.00. Following the sale, the insider owned 123,059 shares of the company's stock, valued at approximately $16,353,310.51. This trade represents a 2.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Steven Leonard Chapman sold 5,807 shares of the firm's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $132.88, for a total value of $771,634.16. Following the completion of the sale, the chief executive officer directly owned 163,593 shares in the company, valued at approximately $21,738,237.84. This represents a 3.43% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,239 shares of company stock worth $8,986,542. 5.63% of the stock is owned by insiders.
Institutional Investors Weigh In On Natera
Several hedge funds have recently modified their holdings of NTRA. Guided Capital Wealth Management LLC raised its position in Natera by 0.5% during the 2nd quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company's stock worth $2,219,000 after purchasing an additional 66 shares during the last quarter. Fulton Bank N.A. raised its position in Natera by 2.0% during the 1st quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company's stock worth $516,000 after purchasing an additional 71 shares during the last quarter. Wedmont Private Capital raised its position in Natera by 4.9% during the 2nd quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company's stock worth $256,000 after purchasing an additional 74 shares during the last quarter. Compound Planning Inc. raised its position in Natera by 4.2% during the 1st quarter. Compound Planning Inc. now owns 1,914 shares of the medical research company's stock worth $271,000 after purchasing an additional 78 shares during the last quarter. Finally, QRG Capital Management Inc. raised its position in Natera by 1.5% during the 1st quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock worth $766,000 after purchasing an additional 81 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.
About Natera
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.